AbbVie (ABBV) Equity Ratio (2012 - 2026)
AbbVie (ABBV) reported Equity Ratio of 0.05 for Q1 2026, down 554.27% year-over-year from 0.01 in Q1 2025, and down 99.81% on a QoQ basis from 0.02 in Q4 2025.
AbbVie (ABBV) has 15 years of Equity Ratio data on file, last reported at 0.05 in Q1 2026.
- Quarterly Equity Ratio fell 554.27% year-over-year to 0.05 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 0.05 (down 554.27% YoY) and the FY2025 annual result came in at 0.02, down 198.08% from the prior year.
- Equity Ratio eased to 0.05 in Q1 2026 per ABBV's latest filing, from 0.02 in the prior quarter.
- Across five years, Equity Ratio topped out at 0.12 in Q4 2022 and bottomed at 0.05 in Q1 2026.
- The 5-year median for Equity Ratio is 0.05 (2024), against an average of 0.05.
- The widest annual swing landed in 2022, when Equity Ratio increased 24.84%; it then sank 554.27% in 2026.
- Tracing ABBV's Equity Ratio over 5 years: stood at 0.12 in 2022, then sank by 38.03% to 0.08 in 2023, then sank by 67.75% to 0.02 in 2024, then plunged by 198.08% to 0.02 in 2025, then plunged by 99.81% to 0.05 in 2026.
- Per Business Quant, the three latest ABBV Equity Ratio figures stand at 0.05 (Q1 2026), 0.02 (Q4 2025), and 0.02 (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Equity Ratio (Qtr) |
|---|---|---|---|---|---|
| 1 | Novartis Ag | 107,124,802.25 Bn | 107,124,802.25 Bn | - | - |
| 2 | Eli Lilly | 969.00 Bn | 963.72 Bn | 16.22 Bn | 0.27 |
| 3 | Johnson & Johnson | 539.46 Bn | 517.41 Bn | 15.96 Bn | 0.40 |
| 4 | AbbVie | 376.92 Bn | 367.57 Bn | 10.78 Bn | -0.05 |
| 5 | Merck | 285.00 Bn | 279.35 Bn | 12.09 Bn | 0.36 |
| 6 | Amgen | 177.58 Bn | 165.55 Bn | 5.87 Bn | 0.10 |
| 7 | Gilead Sciences | 163.22 Bn | 155.50 Bn | 5.52 Bn | 0.42 |
| 8 | Pfizer | 145.86 Bn | 133.09 Bn | -1.21 Bn | 0.43 |
| 9 | Bristol Myers Squibb | 111.90 Bn | 101.44 Bn | 8.07 Bn | 0.23 |
| 10 | Gsk | 88.34 Bn | 83.66 Bn | - | 0.27 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -0.05 |
| Dec 31, 2025 | -0.02 |
| Sep 30, 2025 | -0.02 |
| Jun 30, 2025 | 0.00 |
| Mar 31, 2025 | 0.01 |
| Dec 31, 2024 | 0.02 |
| Sep 30, 2024 | 0.04 |
| Jun 30, 2024 | 0.05 |
| Mar 31, 2024 | 0.05 |
| Dec 31, 2023 | 0.08 |
| Sep 30, 2023 | 0.09 |
| Jun 30, 2023 | 0.10 |
| Mar 31, 2023 | 0.10 |
| Dec 31, 2022 | 0.12 |
| Sep 30, 2022 | 0.11 |
| Jun 30, 2022 | 0.10 |
| Mar 31, 2022 | 0.11 |
| Dec 31, 2021 | 0.11 |
| Sep 30, 2021 | 0.09 |
| Jun 30, 2021 | 0.09 |
| Mar 31, 2021 | 0.09 |
| Dec 31, 2020 | 0.09 |
| Sep 30, 2020 | 0.10 |
| Jun 30, 2020 | 0.10 |
| Mar 31, 2020 | -0.08 |
| Dec 31, 2019 | -0.09 |
| Sep 30, 2019 | -0.14 |
| Jun 30, 2019 | -0.15 |
| Mar 31, 2019 | -0.14 |
| Dec 31, 2018 | -0.14 |
| Sep 30, 2018 | -0.04 |
| Jun 30, 2018 | -0.05 |
| Mar 31, 2018 | 0.05 |
| Dec 31, 2017 | 0.07 |
| Sep 30, 2017 | -0.02 |
| Jun 30, 2017 | 0.00 |
| Mar 31, 2017 | -0.02 |
| Dec 31, 2016 | 0.07 |
| Sep 30, 2016 | -0.02 |
| Jun 30, 2016 | 0.00 |
| Mar 31, 2016 | -0.02 |
| Dec 31, 2015 | 0.07 |
| Sep 30, 2015 | 0.00 |
| Jun 30, 2015 | -0.04 |
| Mar 31, 2015 | -0.04 |
| Dec 31, 2014 | 0.06 |
| Sep 30, 2014 | -0.03 |
| Jun 30, 2014 | 0.18 |
| Mar 31, 2014 | 0.16 |
| Dec 31, 2013 | 0.15 |
| Sep 30, 2013 | 0.13 |
| Jun 30, 2013 | 0.13 |
| Mar 31, 2013 | 0.11 |
| Dec 31, 2012 | 0.01 |